Physician profile
Steven D Young
NPI 1215031943
$250,563.88
in general payments reported to CMS, 2019-2025
25 companies · $57K in 2025
The $57K reported for 2025 was more than what 95% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $27K · 2021: $33K · 2022: $33K · 2023: $37K · 2024: $37K · 2025: $57K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $130K · Food and Beverage: $536.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $129,705.85 |
| Food and Beverage | $535.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $249,161.87 | 2019-2025 | Q-Fix |
| Amgen INC. | $239.41 | 2020-2024 | Evenity, Prolia, Krystexxa |
| Depuy Synthes Sales INC. | $222.74 | 2019-2021 | |
| Endo Pharmaceuticals INC. | $153.68 | 2019-2024 | Xiaflex |
| Stryker Corporation | $150.68 | 2023-2024 | Variax, Mako, Triathlon |
| Elite Orthopedics, LLC | $91.30 | 2021-2025 | |
| Endo USA, INC. | $78.72 | 2024-2025 | Xiaflex |
| Zimvie INC. | $68.48 | 2022-2023 | |
| Ferring Pharmaceuticals INC. | $52.44 | 2019-2021 | |
| Allergan, INC. | $44.22 | 2019-2020 | |
| Pacira Therapeutics, INC. | $35.95 | 2019-2020 | |
| Highridge Medical LLC | $35.85 | 2025 | Biomet Ebi Bone Healing System |
| Ebi, LLC | $35.85 | 2025 | Biomet Ebi Bone Healing System |
| Abbvie INC. | $30.23 | 2021-2022 | |
| Pfizer INC. | $28.74 | 2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fidia Pharma USA INC. | $26.39 | 2019-2020 | |
| Kci USA, INC. | $19.28 | 2021 | |
| Radius Health, INC. | $14.61 | 2025 | Tymlos |
| Sonex Health, INC. | $12.63 | 2021 | |
| Zimmer Biomet Holdings, INC. | $12.30 | 2020 | |
| Sanofi-Aventis U.S. LLC | $11.83 | 2019 | |
| Joint Active Systems, INC. | $11.07 | 2019 | |
| Horizon Therapeutics Plc | $11.04 | 2021 | |
| Polynovo North America LLC | $10.13 | 2021 | |
| Kerecis Limited | $4.44 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.